STORM Therapeutics Logo

STORM Therapeutics selects first-in-class clinical candidate targeting METTL3

22 October 2020, Cambridge, UK: Seroba’s investee company, STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, has announced┬á that STC-15, its first-in-class drug candidate targeting METTL3, has been selected for development towards first in human clinical studies. The Company intends to submit an IND …

STORM Therapeutics selects first-in-class clinical candidate targeting METTL3 Read More »